share_log

Shanghai Universal BiotechLtd's (SZSE:301166) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Shanghai Universal BiotechLtd's (SZSE:301166) Sluggish Earnings Might Be Just The Beginning Of Its Problems

上海環球生物技術有限公司(深圳證券交易所代碼:301166)的低迷收益可能僅僅是其問題的開始
Simply Wall St ·  05/03 18:29

The market rallied behind Shanghai Universal Biotech Co.,Ltd.'s (SZSE:301166) stock, leading do a rise in the share price after its recent weak earnings report. Sometimes, shareholders are willing to ignore soft numbers with the hope that they will improve, but our analysis suggests this is unlikely for Shanghai Universal BiotechLtd.

市場上漲,落後於上海環球生物技術有限公司。, Ltd. 's(深圳證券交易所股票代碼:301166)股票在最近公佈疲軟的業績後股價上漲。有時,股東願意忽視軟數字,希望這些數字能有所改善,但我們的分析表明,對於上海環球生物技術有限公司而言,這不太可能。

earnings-and-revenue-history
SZSE:301166 Earnings and Revenue History May 3rd 2024
SZSE: 301166 收益和收入歷史記錄 2024 年 5 月 3 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

Importantly, our data indicates that Shanghai Universal BiotechLtd's profit received a boost of CN¥4.5m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. We can see that Shanghai Universal BiotechLtd's positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

重要的是,我們的數據表明,與去年相比,上海環球生物技術有限公司的不尋常項目利潤增加了450萬元人民幣。雖然我們希望看到利潤增加,但當不尋常的物品做出重大貢獻時,我們往往會更加謹慎一些。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。我們可以看到,相對於截至2024年3月的一年中,上海環球生物技術有限公司的積極不尋常項目相對於其利潤相當可觀。在其他條件相同的情況下,這可能會使法定利潤成爲衡量潛在盈利能力的不良指導。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shanghai Universal BiotechLtd.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對上海環球生物技術有限公司的資產負債表分析。

Our Take On Shanghai Universal BiotechLtd's Profit Performance

我們對上海環球生物技術有限公司盈利表現的看法

As previously mentioned, Shanghai Universal BiotechLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Shanghai Universal BiotechLtd's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. In further bad news, its earnings per share decreased in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. When we did our research, we found 4 warning signs for Shanghai Universal BiotechLtd (2 are concerning!) that we believe deserve your full attention.

如前所述,上海環球生物技術有限公司不會無限期地從不尋常項目中獲得巨額提振,因此其法定收益可能無法指導其潛在盈利能力。出於這個原因,我們認爲上海環球生物技術有限公司的法定利潤可能不利於其潛在盈利能力,並可能給投資者留下過於積極的印象。另一個壞消息是,其每股收益在去年有所下降。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。當我們進行研究時,我們發現了上海環球生物技術有限公司的4個警告信號(2個令人擔憂!)我們認爲值得你全神貫注。

This note has only looked at a single factor that sheds light on the nature of Shanghai Universal BiotechLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

這份報告只考慮了揭示上海環球生物技術有限公司利潤性質的單一因素。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論